Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorGuy's and St Thomas' NHS Foundation Trust
About this trial
Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.
Eligibility criteria
Qualifiers
Written informed consent
Aged 16 or above
Histologically confirmed HNSCC or NSCLC, who are treatment naïve and scheduled to commence standard of care treatment ((chemo)radiotherapy)
Willingness and ability to comply with scheduled study visits and tests
Disqualifiers
Pregnant or lactating women
Concomitant uncontrolled medical conditions
Participants likely to require palliative radiotherapy within the first 12 weeks of treatment
Prognosis less than 3 months
Trial design
Treatments tested in this trial
- 18F-FSPG PET/CT in NSCLC
- 18F-FSPG PET/CT in HNSCC
Treatment groups
32 Participants
are divided into 2 treatment groupsLocations
1Guy's and St Thomas' NHS Foundation Trust London United Kingdom
Sponsors and collaborators
Guy's and St Thomas' NHS Foundation Trust
Lead sponsor
King's College London
Collaborator
Source ClinicalTrials.gov